Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

CRI Technology Impact Award

Cancer Research Institute

The CRI Technology Impact Award is designed to support early-stage, pre-development concepts — innovations that have not yet been built or tested, but that hold the potential to transform the landscape of cancer immunotherapy.

Focus and Scope

The CRI Technology Impact Award aims to bridge the gap between conceptual technological innovation and real-world clinical application. By encouraging collaboration between technology
developers and clinical cancer immunologists, CRI hopes to accelerate the creation of technologies that can generate proof-of-principle data and unlock novel biological insights.

Technology Impact Awards are not intended to fund the continuation or refinement of existing technologies. Instead, they support visionary, high-risk/high-reward ideas that could lay the groundwork for a new generation of tools, platforms, and systems capable of overcoming the most critical barriers in the field. Proposals that fundamentally apply existing technologies (e.g. scSeq, spatial seq, etc.) without substantial instrumentation, device, or algorithm development will typically be considered non-responsive.

The most competitive applicants will propose innovations that address areas where technological advancement can have the greatest impact on cancer immunotherapy and patient outcomes. Such technologies may include, but are not limited to:

Computational systems biology approaches to analyze large-scale datasets, develop more accurate models of underlying cellular and molecular networks, with the goal of better explaining and predicting response/resistance to cancer therapy
Advanced cancer (or molecular) profiling technologies that can be used to identify key barriers to immunotherapy and improve target identification and therapeutic decision-making
Real-time visualization technologies that allow tracking of molecular and cellular immune responses to treatment in mice or humans
Complex multicellular culture systems that model interactions between tumor and the immune system and enable therapeutic testing or mechanistic studies
Novel therapeutic technologies that promise to safely and effectively promote tumor immunity in new ways

Specialties

Cancer

Oncology

Immunology

Others

Eligibility Requirements

Applicants must hold a tenure-track position at a not for profit research center or institution. Clinical cancer immunologists and technology developers are encouraged to collaborate. Co-PIs are eligible and encouraged to apply.

Sponsor Details

Sponsor Institute/Organizations: Cancer Research Institute

Sponsor Type: Corporate/Non-Profit

Address: 29 Broadway, Floor 4 New York, NY 10006

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity